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Background: The project “Quality Assurance in Ambulatory Psychotherapy in Bavaria” 
(QS-PSY-BAY) focuses on the quality assurance of outpatient psychotherapy (OPT) in 
Germany in terms of symptom reduction and cost reduction under naturalistic condi-
tions. In this study, we examined the effectiveness of psychotherapy in terms of pre–post 
cost reduction.
Method: The health-care costs of N =  22,294 insurants over a 5-year period were 
examined in a naturalistic longitudinal design. Six participating health insurance funds 
provided data on costs related to inpatient treatment, outpatient treatment, drugs, and 
hospitalization and work disability days.
results: We found that the average annual total costs for inpatient and outpatient 
treatments as well as drug costs and work disability days increased from the second 
to the first year before OPT. Besides a large and significant reduction of work disability 
days (41.8%), hospitalization days (27.4%), and inpatient costs (21.5%) from the first 
year before versus the first year following OPT, we found evidence for long-term effects: 
the number of work disability days in the second year after OPT was lower (23.8%), and 
drug costs were higher than in the second year before OPT (41.5%).
conclusion: We conclude that OPT as a part of the health insurance system is an 
investment which can pay off in the future especially in terms of lower inpatient costs 
and work disability.
Keywords: health-care utilization, mental disorder, outpatient psychotherapy, cost reduction, economic benefits
inTrODUcTiOn
Health services research focuses on medical and psychotherapeutic treatments under naturalistic 
conditions. Because health expenditures are very large (e.g., in Germany, 11.3% of gross domestic 
product; see OECD Health Statistics 2014) and a considerable proportion of people suffer from 
a mental disorder [e.g., 38.2% in the EU; Ref. (1)], the examination of the monetary aspects of 
psychological treatments becomes increasingly relevant. Multiple reviews and meta-analyses 
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(2–8) suggest that costs and medical treatment utilization after 
psychotherapy are reduced, and that – compared with medical 
treatment – psychotherapy is more effective in terms of symptom 
and cost reduction. In general, psychotherapy seems to be cost-
effective, although the available reviews and meta-analyses usu-
ally refer to studies of health-care systems of different countries, 
various psychological approaches, and/or evaluations of different 
cost variables.
In this study, we focused on outpatient psychotherapy (OPT) 
in Germany. In general, little is known about the cost-effectiveness 
of OPT (3). The examination of the cost-effectiveness of psycho-
therapy is subject to the problem that studies come from various 
health services systems with different general conditions for OPT. 
The number of therapy sessions, e.g., provides one marked differ-
ence: in the USA, e.g., the median number of OPT sessions is 5, 
whereas in German, short-term psychotherapy comprises 25 ses-
sions (9). For this reason, results related to therapy outcome or its 
cost-effectiveness are not directly comparable between countries.
In Germany, three approaches of psychological treatment 
are part of the health insurance system: cognitive behavioral 
psychotherapy (CBT), psychodynamic psychotherapy (PDP), 
and psychoanalytic (long-term) psychotherapy (PP). In all three 
approaches, the first five sessions are seen as “probatory” sessions 
in which patients’ psychological and social problems are clari-
fied and the corresponding mental disorders are diagnosed. The 
subsequent therapy sessions must be requested from the health 
insurance fund. Usually, it is distinguished between short-term 
(up to 25 sessions) and long-term psychotherapies (50 sessions 
and more). Both forms can be extended in case of a complex men-
tal disorder and therapy progress [for more details, see Ref. (10)].
Two issues will mainly be focused in health-care utilization 
research: the first is the examination of treatment costs related to 
specific mental disorders. For depressive patients, for example, 
Salize et al. (11) reported that the mean annual costs of medical 
care were €3849. For patients with alcoholic addiction, Stamm 
et  al. (12) reported that the mean expenditure by a health 
insurance company on insurants with a one-time diagnosis in 
the reference year was €2888.97, whereas it was €5261.82 for 
chronic alcoholics. In their review of the costs of schizophrenia in 
Germany, Konnopka et al. (13) found that the direct annual costs 
per person varied between €14,000 and €18,000 and costs related 
to the loss of productivity varied between €25,000 and €30,000.
A second issue is the examination of cost reduction as a con-
sequence of psychotherapy. Comparing the first year before with 
the first year after OPT, Kraft et al. (14) reported a 6.7% reduction 
of medical costs from €3717.92 to €3468.47. In addition, days 
of hospitalization were reduced between 1.8 and 19.8 (14–17). 
The number of work disability days as an aspect of indirect costs 
has also been studied. Multiple studies (15, 17–20) reported a 
decrease of 3.0–19.6 days, when comparing the first year before 
with the first year after OPT (for more details, see Table S1 in 
Supplementary Material).
Taken together, the studies mentioned above reported reduc-
tions in multiple cost factors in the context of OPT in Germany. 
The most recent study dates back to 2006, and all the sample 
sizes were under 700 insurants (see Table S1 in Supplementary 
Material). In these studies, missing data were not imputed, so 
that – due to list-wise deletion – selection bias can be assumed. 
Furthermore, the reduction of costs varies widely among studies, 
which could be due to small samples and distortions caused by 
high cost cases and/or sampling bias. An examination of a large 
and representative sample is needed to evaluate the quality of 
outpatient therapy in Germany in terms of cost reduction.
The project “Qualitätssicherung in der ambulanten 
Psychotherapie in Bayern” (“Quality Assurance in Ambulatory 
Psychotherapy in Bavaria;” QS-PSY-BAY) focuses on the quality 
assurance of German OPT under naturalistic conditions (21–23). 
We were interested in both, the effectiveness of OPT and mon-
etary aspects like cost reduction. Previous analyses have focused 
on a subsample with N ≈ 1700 patients, including questionnaire 
data. The results lead to the following conclusions (21–26): under 
naturalistic conditions, OPT is effective in reducing symptom 
intensity and improving quality of life – even in the case of pre-
mature discontinuation; the dosage of psychotherapy obviously is 
adapted to treatment conditions and the severity of the patient’s 
illness.
In this study, we focus on the monetary aspect of OPT. 
Analyzing health insurance data of 22,294 persons with statutory 
health insurance, we examined inpatient costs, outpatient costs, 
drug costs, number of work disability days, and number of hospi-
talization days under naturalistic conditions. According to Kraft 
et al. (27), we hypothesized (1) that health-care costs increase in 
the time before a person will be treated with OPT and (2) that 
health-care costs should be reduced from pre- to posttreatment.
MaTerials anD MeThODs
sample
The sampling was performed by the Kassenärztliche Vereinigung 
Bayerns (KVB; Bavarian Association of Compulsory Health 
Insurance Physicians). A random sample of N = 38,338 persons 
was generated. Inclusion criteria were (1) the person was insured 
by one of the six participating statutory health insurance, (2) age 
over 18 years, (3) diagnosis of mental disorder (ICD10: F2–F6) 
except dementia (ICD10: F0) and addiction (ICD10: F1), and (4) 
treated with individual OPT. All inclusion criteria should apply 
for the reference quarter (billing date at third quarter of the year 
2008). In the German health system at the time, the study was 
planned, addiction and dementia are not treated in an OPT 
setting. We selected 22,294 out of the 38,338 insurants whose 
start and end of psychotherapy could be identified based on cost 
data (see Data Preprocessing). Table 1 shows the distribution of 
gender, age, place of residence, and the frequency of the different 
psychotherapeutic approaches.
It should be noted that the examined sample is rather het-
erogeneous regarding mental disorders and psychotherapeutic 
treatments. The distribution of psychotherapeutic approaches 
was CBT 46.1%, PDP 48.6%, and PP 5.3%. The 35.5% insurants 
additionally received various psychotropic drugs [antipsychotics 
(ATC Code: N05A), anxiolytics (N05B), hypnotics and sedaticies 
(N05C), antidepressants (N06A)]. The mean duration of psycho-
therapy was M = 31.3 sessions (Median = 25, SD = 31.3) last-
ing – on an average – for seven quarters (Median = 5, SD = 2.9), 
TaBle 1 | Distribution of age, gender, place of residence, and 
psychotherapeutic approach in the random sample with psychotherapy 
and in the examined subsample of patients, whose begin and end of 
therapy could be identified using cost data.
random sample 
with OPT
examined sample
with OPT
Sample size 38,336 22,294
Men (%) 22.8 23.3
Women (%) 77.2 76.7
Age 18 to <35 (%) 24.7 24.3
Age 35 to <50 (%) 42.9 41.0
Age 50 to <65(%) 27.2 28.5
Age 65–110 (%) 5.2 6.2
Urban agglomeration (%) 48.2 46.0
Urbanized area (%) 25.3 26.2
Rural area (%) 26.6 27.8
Cognitive behavioral therapy (individual 
therapy) (%)
39.8 46.1
Psychodynamic psychotherapy 
(individual therapy) (%)
47.1 48.6
Psychoanalysis (individual therapy) (%) 13.1 5.3
FigUre 1 | Data preprocessing and computation of used time axis.
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i.e., ~21 months. Depending on the psychological approach, the 
mean number of sessions was CBT, M = 30.8; PDP, M = 33.2; and 
PP, M = 94.7.
Outcome respectively cost Variables
The six participating health insurance funds provided inpatient 
treatment costs, drug costs, and information about hospitaliza-
tion and work disability days. The KVB, on the other hand, pro-
vided outpatient treatment cost data for the sample. These data 
were matched by anonymous one-to-one identification number. 
We obtained information about demographic variables (e.g., 
gender, year of birth, and category for the domicile), inpatient and 
outpatient treatments (e.g., diagnosis, treatment, physician group 
of the treating physician/psychotherapist, treatment time point, 
and costs), prescription of drugs (e.g., drug type, price), and work 
disability days for the time interval from 2006 Q1 to 2010 Q3 (cf., 
Figure 1). We obtained no data about insurance status (e.g., date 
of change the health-care fund), family background, rehabilita-
tion, and dental treatments.
Data Preprocessing
First, for each cost variable, we aggregated the individual cost 
entries for each quarter. To identify which cost entry related to 
the quarter of interest, we used the performance date (not the 
payment date). If the time interval of work disability or hospitali-
zation extended more than one quarter, we splitted the interval 
accordingly. With the quarterly aggregation, the background for 
a cost entry was lost. For example, a quarterly total of outpatient 
treatment costs could have been caused by flu, knee injury, as well 
as mental disorder treatment, or even by a mixture of treatments.
In a next step, we distinguished between healthy individuals 
and those whose health-care costs were not documented, for 
example, due to a change in their health-care fund or caused by 
death. In both cases, we did not find any entry for such persons 
in the quarter of interest. Hence, for each person, we identified 
the earliest entry across all variables (e.g., work disability days in 
2006 Q4) and the latest entry (e.g., outpatient costs in 2009 Q4). 
Within this individual “trust interval” (in our example between 
2006 Q4 and 2009 Q4), quarters without cost entries were set 
to 0 because we could assume that the person was healthy (see 
Figure 1). Empty quarters outside the trust interval were coded 
as missing value (see Figure 1).
We then identified the beginning and the end of OPT for each 
person (Figure 1), assuming that quarter t is the first quarter of the 
OPT if quarter t − 1 contained no entry for a treatment. Similarly, 
we assumed that the therapy ended in quarter t if quarter t + 1 
4Altmann et al. Psychotherapy Reduces Health-Care Costs
Frontiers in Psychiatry | www.frontiersin.org June 2016 | Volume 7 | Article 98
revealed no entry for OPT. The time interval of the examined 
OPT had to include the reference quarter 2008 Q3; otherwise, the 
insurant was excluded from data analysis.
Furthermore, we aligned the individual time courses of the 
cost variables to the beginning and end of OPT. We generated a 
time axis, in which negative values indicated quarters before OPT 
and positive values quarters after OPT. Quarters comprising OPT 
were excluded in this time axis (see Figure 1, line “combined time 
axis”). Using such an aligned time course of health-care costs, we 
computed annual totals for the second year before OPT (quarter 
−8 to −5), the first year before OPT (quarter −4 to −1), the first 
year after OPT (quarter 1–4), and the second year after OPT 
(quarter 5–8).
Missing Data
We had complete sociodemographic and cost data for the refer-
ence quarter 2008 Q3 for all insurants. The number of missing 
cost data increased with the temporal distance from the reference 
quarter (number of insurants with missing data: 11,351 of 22,294 
in the eighth quarter before OPT, 2517 in fourth quarter before, 
and 0 in first quarter before and in first quarter after OPT, 4360 
in fourth quarter after OPT, and 17,993 in eighth quarter after 
OPT). For parameter estimation, we used the full-information 
maximum likelihood (FIML) method using all available sociode-
mographic and cost variables as covariates, which is comparable 
with missing-at-random imputation.
Data analysis
Representativeness of Sample
As mentioned above, in the reference quarter (2008 Q3), random 
sample of 38,338 insurants was treated with OPT. From this sam-
ple, N = 22,294 insurants were selected for which the beginning 
and the end of therapy could be identified based on the available 
cost data. Using nominal regression, we examined systematic dif-
ferences between the entire sample and the analyzed subsample. 
The potential predictors for selection effects were age group, 
gender, place of residence, and psychotherapeutic approach. The 
outcome variable was a binary variable, which indicates with 1 
and 0 that a person was included in the examined sample. Based 
on χ2-statistics of nominal regression, we computed Cramer’s V as 
an effect size measure. According to Rea and Parker (28), Cramer’s 
V can be interpreted as negligible (0–0.1), weak (0.1–0.2), moder-
ate (0.2–0.3), relatively strong (0.4–0.6), strong (0.6–0.8), or very 
strong (0.8–1.0). Furthermore, the fit of nominal regression in 
terms of Nagelkerke R2 was considered. According to Cohen 
(29), R2 can be interpreted as small (0.0196–0.13), moderate 
(0.13–0.26), and large (0.26–1.0).
Comparison of Annual Totals
To study the effect of psychotherapy in terms of cost reduction, 
we computed annual totals for each cost variable. We focused 
on the second and the first year before the beginning of OPT, 
as well as on the first and the second year after end of OPT. An 
individual annual total represents the sum of the corresponding 
quarterly totals. The averages of the annual totals were compared 
conducting a t-test for paired samples. The level of significance 
was α = 0.05.
resUlTs
representativeness of sample
Using nominal regression and the predictors’ age, gender, place 
of residence, and psychotherapeutic approach, we examined the 
representativeness of our examined sample of N =  22,294 (for 
descriptive statistics, see Table 1). Except place of residence all 
variables significantly predicted the fact if a person is or  is not 
part of the examined subsample (gender: χdf = =1
2 6 5. , p = 0.011, 
Cramer’s V  =  0.013; age: χdf = =32 105 8. , p  <  0.001, Cramer’s 
V =  0.053; place of residence: χdf = =22 5 2. , p =  0.076, Cramer’s 
V = 0.012; and psychological approach: χdf = =22 2853 3. , p < 0.001, 
Cramer’s V = 0.273). Despite significant differences, the corre-
sponding effect sizes for gender, age group, and place of residence 
can be interpreted as negligible (Cramer’s V < 0.1), whereas the 
psychotherapeutic approach seems to be the only relevant selec-
tion effect since the effect size can be interpreted as moderate. The 
model fit of nominal regression points into the same direction: 
Nagelkerke R2 was 0.107, indicating that 10.7% of the outcome 
variable’s variance can be explained by the regression with age 
group, gender, place of residence, and psychotherapeutic approach 
as predictors. Running the model without the treatment variable, 
Nagelkerke R2 was only R2 = 0.011, which is smaller than the cut-
off value for small effects. It also means that the psychotherapeu-
tic approach explains 9.6 = 10.7 − 1.1% of the variance and that 
the selection process is mostly driven by the psychotherapeutic 
approach. On average, psychoanalytic long-term treatment was 
underrepresented in our examined subsample (see Table 1).
costs before and after Outpatient 
Psychotherapy
The means of the quarterly totals are shown in Figure 2, and the 
means of the annual totals in Figure 3. It can be seen that work 
disability days and inpatient cost increased considerably before 
OPT and decreased to their initial values following OPT.
In Table 2, the means of the annual totals are listed. Comparing 
1 year before and 1 year after psychotherapy, the inpatient costs, 
outpatient costs, work disability days, and hospitalization days 
were reduced significantly (see also Table 3). Furthermore, in the 
second year after psychotherapy, the work disability days were 
significantly lower than in the second year before psychotherapy. 
In the second year after psychotherapy, days of hospitalization, 
inpatient costs, and outpatient cost were on similar level as in 
the second year before psychotherapy. In contrast to all the other 
variables, we found significant growth in drug costs. Taking inpa-
tient, outpatient, and drugs costs together, the total cost reduced 
from the first year before to the first year after OPT, which means 
that the reduction of inpatient and outpatient costs predominated 
the growth of drug costs.
DiscUssiOn
Outpatient psychotherapy is effective in terms of symptom 
reduction and the improvement of quality of life (23). Little is 
known about the cost-effectiveness of OPT (3), especially related 
to recent and representative data. Accordingly, we examined the 
FigUre 3 | annual costs before and after outpatient psychotherapy 
(means and their 95% confidence intervals; at each time point, 
N = 22,294).
FigUre 2 | Time course of cost variables (means of quarterly totals 
and 95% confidence intervals; negative time values indicate quarters 
before outpatient psychotherapy and positive time values quarter 
after psychotherapy; at each time point, N = 22,294).
TaBle 2 | averages of annual total costs before and after outpatient 
psychotherapy.
averages of annual 
totals
second year 
before
First year 
before
First year 
after
second 
year after
Inpatient costs (€) 1097.36 1642.90 1289.05 1147.39
Outpatient costs (€) 854.40 947.41 872.21  913.38
Drug costs (€) 513.87 630.04 735.28  727.17
Total costs (€) 2465.63 3220.35 2896.54 2787.95
Work disability days 16.01 27.57 16.04   12.20
Hospitalization days 4.08 7.35 5.33    4.42
The sample size is N = 22,294.
TaBle 3 | comparison of annual totals before and after outpatient 
psychotherapy.
diff (SE) diff in % ES
second before vs. first after
Inpatient costs (€) 545.54*** (50.94) 49.7 0.071
Outpatient costs (€) 93.01*** (8.08) 10.9 0.077
Drug costs (€) 116.17*** (12.97) 22.6 0.060
Total costs (€) 754.72*** (54.22) 30.6 0.093
Work disability days 11.56*** (0.44) 72.2
Hospitalization days 3.27*** (0.19) 80.1
First before vs. first after
Inpatient costs (€) −353.84*** (49.17) −21.5 0.048
Outpatient costs (€) −75.20*** (8.03) −7.9 0.063
Drug costs (€) 105.23*** (17.34) 16.7 0.041
Total costs (€) −323.80*** (53.79) −10.1 0.040
Work disability days −11.53*** (0.48) −41.8 0.161
Hospitalization days −2.02*** (0.19) −27.4 0.071
second before vs. second after
Inpatient costs (€) 50.04n.s. (59.55) 4.6 0.006
Outpatient costs (€) 58.98*** (12.86) 6.9 0.031
Drug costs (€) 213.30*** (25.84) 41.5 0.055
Total costs (€) 322.32*** (69.79) 13.1 0.031
Work disability days −3.82*** (0.53) −23.8 0.048
Hospitalization days 0.35n.s. (0.21) 8.6 0.011
The sample size is N = 22,294.
***p < 0.001.
n.s.p ≥ 0.05.
diff, absolute difference; diff in %, difference as percent of pretreatment value; ES, 
effect size.
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cost reduction in the context of OPT in Germany under natural-
istic conditions.
increasing heath-care cost before 
Outpatient Psychotherapy
Looking at the quarterly means before the OPT, we found that 
the outpatient costs are relatively stable, whereas inpatient costs, 
drug costs, hospitalization days, and work disability days began to 
increase around four quarters before OPT (Figure 2). This find-
ing can be interpreted in different ways. First, it is possible that 
an insurant with an untreated (or undiagnosed) mental disorder 
might be “going around” and tries out various (inpatient and/or 
pharmacological) treatments until he/she finds the adequate out-
patient psychological treatment. Another interpretation is that a 
mental disorder might be triggered by a hospitalization (30) and 
subsequently treated within an outpatient setting. Additionally, 
6Altmann et al. Psychotherapy Reduces Health-Care Costs
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the time courses of cost variables indicate that an outpatient 
psychotherapeutic treatment might also be a continuation of 
inpatient psychotherapeutic treatments. We assume that all 
explanations might partly apply. However, future research should 
take time courses of cost variables into the account, depending 
on pretreatments before OPT (e.g., psychotherapy of PTSD after 
ICU stay).
Furthermore, we found that costs during the time to find an 
adequate treatment of mental disorder are high, for example, 
the annual inpatient cost increased from €1097.36 to €1642.90 
(mean annual totals) and the annual work disability days from 
16.01 to 27.57 days (see Table 2). These annual costs were smaller 
than the annual means reported by Kraft et al. (27), but similar 
related to the cost medians. The difference between both studies 
might be caused by a methodological issue: the small sample of 
Kraft et al.’s (27) study (N = 708) is more sensitive to high cost 
cases than the large sample (N = 22,294) in our study. However, 
the study by Kraft et  al. (27) and our results suggest that an 
untreated mental disorder is associated with increasing costs. 
This finding affects the issue of waiting times for OPT, which 
is currently discussed in Germany [according to recent studies, 
e.g., Ref. (31), the average waiting time is 3  months from the 
first contact to the first session, with a considerable variance 
depending on the geographical region]. Furthermore, studies 
should focus on the dependency between increasing costs and 
the time between diagnosis of mental disorder and beginning of 
OPT. It can be assumed that health-care costs could be reduced 
by shorter waiting periods (2).
reduction of health-care cost after 
Outpatient Psychotherapy
For the examination of cost reductions, we compared the aver-
age annual totals 1 year before and 1 year after OPT. Outpatient 
costs were reduced by €75.20 (7.9% of the annual total 1  year 
before psychotherapy), inpatient costs by €353.84 (21.5%), hos-
pitalization days by 2.02 days (27.4%), and work disability days 
by 11.53 days (41.8%) (Table 3). These cost reductions differ from 
the findings of other studies, which could be explained by a differ-
ent distribution of the psychological approaches and the sample 
composition. Breyer et al. (19) and Keller et al. (17), for example, 
reported less reduction in work disability days for patients treated 
with psychoanalysis (8.6 and 6.4 days, respectively). Jacobi (16), 
who studied only CBT for anxiety disorder, reported a higher 
number than our study (19.8  days). Kraft et  al. (14) examined 
only CBT and PDP and reported less reduction of medical costs 
(€249.45, respectively, 6.7%). However, like other studies, our 
study shows that OPT is cost-effective in terms of cost reduction.
Contrary to these findings, drug costs increased significantly 
by €105.23 (respectively, 16.7%) between the first year before OPT 
and the first year after OPT (see Table 3) in our study. This sug-
gests that some persons probably started with a pharmacological 
treatment after OPT. Possibly, this finding reflected various price 
increases. Future studies should also examine the frequency and 
conditions of such subsequent treatments (e.g., due to which 
disorder, severity of disorder, risk of relapse, therapeutic failure of 
OPT, etc.). However, the reduction of the inpatient and outpatient 
cost was larger than the increase of the drug cost, resulting in a 
total cost reduction of €32.80 (10.1%).
We also found evidence for long-term effects of OPT (Table 3): 
in the second year after OPT, the annual work disability days were 
lower than in the second year before therapy. This suggests that 
OPT not only reduces the costs but also increases psychosocial 
functioning of a patient with respect to lowering the number of 
work disability days.
Altogether, our results are in line with the review of Gabbard 
et al. (4), who stated that much of the impact of OPT is related to 
reductions in inpatient treatment and decreases in work impair-
ment. Despite support for a cost reduction, one should not forget 
that monetary aspects are not the only criterion for the evalua-
tion of a psychotherapeutic treatment. Effectiveness in terms of 
symptom reduction and improvement of life quality still should 
be the primary criterion; accordingly, it would be of interest to 
compare treatments with similar effectiveness related to their 
monetary aspects (2).
limitations of the study
In this study, we examined cost data referring to a time interval 
of 5 years provided by multiple health insurance funds. Starting 
from a random sample (N = 38,338) of Bavarian insurants who 
were treated with OPT, we selected a sample (N = 22,294) where 
the beginning and the end of the OPT could be clearly identified. 
With regard to gender, age, and place of residence, this subsample 
did differ in a negligible way from the initial random sample. 
We found that gender and age group significantly predicted the 
inclusion into the examined sample, but the corresponding effect 
sizes were almost negligible (Cramer’s V < 0.1), whereas PP was 
underrepresented in our examined sample (Cramer’s V = 0.27, 
respectively, moderate effect size). This limitation might be 
caused by the fact that PP usually comprises much more therapy 
sessions than CBT and PDP. Accordingly, the beginning and the 
end of therapy might have been underrepresented within our 
5-year study interval leading to an exclusion of more patients. 
This problem could only be solved within study intervals lasting 
longer than 5 years.
The identification of the beginning and the end of the thera-
pies might be a subject of discussion, since the health insurance 
funds did not provide explicit information. The start and the end 
of therapy were identified by detecting the quarters in which no 
OPT was accounted for (Figure 1). This method fails if an insured 
person waits for a therapy extension for longer than one quarter. 
However, we assumed that such cases are very rare and that the 
resulting bias is tolerable given our large sample.
Another problem concerns the correct identification of the 
quarter in which a person is “healthy” in the sense of causing 
no costs for the insurance company. In our database, an insured 
person is only “visible” if he/she causes treatment costs. Before the 
earliest entry and after the last entry, it could be (1) that the insur-
ant was “healthy” and causing no costs or (2) that he/she changed 
the health-care fund and prompted no further entries under the 
“old” identification number. This could be a general problem for 
health insurance data analysis, since the time-dependent sample 
sizes of Kraft et al. (14) suggested that they had the same prob-
lem. All reported problems are quite typical for the analysis of 
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health insurance fund data as we realized throughout the project 
[cf., Ref. (23)].
Compared with other studies related to monetary aspects of 
OPT in Germany, our study has at least two strengths: first, our 
large sample (N = 22,294) is unique compared with other studies 
(N < 700; see Table S1 in Supplementary Material). The larger size 
of our sample contributes to the fact that our estimations will be 
more accurate, e.g., in terms of smaller standard errors. Second, 
our data came from more than one health insurance fund. This 
avoids selection bias, since sociodemographic characteristics and 
the prevalence of chronic diseases differ between health insur-
ance funds (32). As a consequence, in a sample confined to one 
health insurance fund, the average costs might be biased.
One important aspect in the discussion relates to the question 
if and how treatment costs and conditions may change over time: 
during our study, six different legal initiatives relevant to health 
care were passed. Such changes cannot be avoided in naturalistic 
long-term sectional studies about health-care costs. In addition, 
inflation [in Germany, 1.5% per year between 2000 and 2010 (33)] 
and changes in the per capita health expenditure [in Germany, 
3% growth per year between 2000 and 2010 (34)] can be seen 
as confounders. Some researchers adjust their data by applying 
cost reduction with regard to inflation and growth of per capita 
health expenditures. We decided to set such an adjustment aside 
to obtain a more conservative estimate.
cOnclUsiOn
The reduction of health-care costs in the context of OPT suggests 
that – under naturalistic conditions – OPT as part of the health-
care system can be seen as an investment, which will pay off in 
the future in terms of reduced costs for inpatient treatment and a 
decrease of the number of work disability days.
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